Inhibition of SIRP-gamma for cancer treatment
AssigneeAmgen Inc.
InventorsRuozhen Hu, Paolo Manzanillo, Wenjun Ouyang
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating a subject with a tumor or cancer. In exemplary embodiments, the method comprises increasing an immune response against the tumor or cancer in the subject or increasing effector activity or reducing suppressive activity of T-cells in the subject. In exemplary embodiments, the method comprises administering to the subject a SIRPγ binder, e.g., SIRPγ inhibitor, in an amount effective to treat the tumor or cancer in the subject.
Claims9
A method of treating a subject with a tumor or cancer, the method comprising administering to the subject an anti-signal regulatory protein gamma (SIRPγ) antibody comprising a means for binding SIRPγ at the interface between Immunoglobulin (Ig) Domain 1 (D1) and Ig Domain 2 (D2) of SIRPγ, in an amount effective to treat the tumor or cancer in the subject.
Dependencies are inferred from the claim text.